Complement factor B inhibitors and uses there of

US9475806B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Christopher M. Adams · Arlington, US
• Charles BABU · Arlington, US
• Michael Paul Capparelli · Cambridge, US
• Jian Ding · Shanghai, CN
• Takeru Ehara · Tsukuba, JP
• Keith Jendza · Boston, US
• Nan Ji · Arlington, US
• Rajeshri Ganesh Karki · Somerville, US
• Toshio Kawanami · Belmont, US
• Liang Xue · Arlington, US
• Nello Mainolfi · Belmont, US
• James J. Powers · Waltham, US
• Michael H. Serrano-Wu · Cambridge, US
• Chun Zhang · Waltham, US

Key dates

• Filing date: Mar 13, 2014
• Grant date: Oct 25, 2016
• Expiry date: Mar 13, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.